Rivulet Media Inc (fka RIVU)

[ospreyeye]

BMSN: Good Morning Traders,



There has been much anticipation regarding todays profile. I have received many emails speculating on what the potential company might be.



Your wait is over and we are immediately turning all of our attention toward BMSN.



BMSN has been trading on a steady amount of interest recently and we are anticipating a move as we see that the slow and steady move up the charts off of its recent lows indicates that it is under accumulation as we speak. We believe that the breakout is imminent.



Take a look at the chart:



Take a look back to mid-January when BMSN was sitting just below its current levels after it already mad an impressive move from late last year. BMSN went on to hit a high of 1.65, which represented a gain of 8000 percent off of its lows on steady volume.



After much expected profit taking, BMSN then settled down and traded in an extremely tight channel on steady but light volume.



Over the past few sessions interest has been picking up and the pps is moving in the right direction in relation. In fact, we have seen BMSN close in the green on 8 out of the last 10 sessions. BMSN traded 90,000 % above the 3 month average volume yesterday.



You tell me if something is up!



Technical indicators are all indicating that BMSN is heading north. The third party technical site STA is saying that BMSN is a BULL right now: http://www.stockta.com/cgi-bin/analysis.pl?symb=BMSN&cobrand=&mode=stock.



BMSN STORY



BMSN operates through its wholly owned subsidiary, Regen BioPharma. Regen BioPharma has assessed over 20,000 stem cell related issued patents, narrowed down to 2000 patents with commercial applicability, and further identified 30 patents available for licensing. The company seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies. Currently there is a major inefficiency in the development of stem cell therapies: companies are set up, large costs are spent on infrastructure development, then when the product fails everything goes to waste. Our approach is to establish an infrastructure that can be used for multiple therapeutic products.



REGEN BIOPHARMA AVOIDS WASTE OF "ONE PRODUCT/ONE INFRASTRUCTURE" APPROACH



In the "Conventional Model", stem cell companies are started with one basic technology, infrastructure is developed around that technology, then if the technology fails, significant resources are lost that have been used in the product-specific development.



BMSN inlicenses multiple products that are related and have science established.



BUSINESS MODEL: The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets.



Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, they aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma.



Start your research on BMSN immediately. I will have more info throughout the day. You can start here: http://finance.yahoo.com/q?s=bmsn&ql=1 & http://www.regenbiopharma.com/index.html





The ImpressivePennyStocks Team




REMEMBER! For our fastest alerts bookmark these pages:

https://twitter.com/ImpressivePS

http://impressivepennystocks.com/category/todays-alerts/

We are committed to providing you the best service in the industry. Please continue to bring us your feedback and comments.